Houston-based biopharmaceutical start-up CoRegen, Inc. has tapped Dr. Sonal Gupta, a 20-year oncology veteran, as its new Chief Medical Officer. Charged with shepherding CoRegen’s steroid-receptor-coactivator-3 (SRC-3) inhibitor through IND filing and into Phase I trials, Gupta arrives after leadership roles at Genentech and Kite Pharma.
Why CoRegen Picked Gupta
Gupta’s dual MD–PhD pedigree and track record guiding T-cell and gene-therapy programs make her “the ideal bridge between discovery and the clinic,” says CEO Bert O’Malley. Her mandate: finalize clinical-trial design, build regulatory dossiers, and establish investigator networks across top U.S. cancer centers.
Market and Mission
SRC-3 over-expression drives resistance in multiple solid tumors; CoRegen’s small-molecule approach has shown pre-clinical promise in pancreatic and triple-negative breast cancers. With Gupta at the helm, the company eyes first-in-human dosing by Q2 2026—positioning itself in a competitive field where Big Pharma is hungry for novel druggable targets.
